Targeted drug delivery and penetration into solid tumors.

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• Chemotherapeutic drug delivery and penetration into tumors are significantly hindered by abnormal tumor vasculature and altered stromal composition.
• Neoplastic tissues present unique barriers to effective drug distribution, impacting treatment efficacy.

Purpose of the Study:

• To explore strategies for improving chemotherapeutic drug delivery and penetration into tumor cells.
• To investigate the potential of tumor vasculature-homing peptides and biological agents in enhancing drug delivery.
• To evaluate the efficacy of Asn-Gly-Arg (NGR)-containing peptides and NGR-tumor necrosis factor-α (NGR-TNF) in overcoming drug delivery barriers.

Main Methods:

• Coupling chemotherapeutic drugs with tumor vasculature-homing peptides, specifically those containing the Asn-Gly-Arg (NGR) motif.
• Administering drugs in combination with biological agents that modulate the integrity of tumor endothelial lining.
• Utilizing NGR-TNF, a fusion protein designed to selectively alter drug penetration barriers, and testing it in a Phase III clinical trial for malignant pleural mesothelioma.

Main Results:

• Asn-Gly-Arg (NGR)-containing peptides show promise as ligands for targeted drug delivery to tumor vasculature.
• NGR-TNF demonstrates the ability to selectively alter drug penetration barriers within tumors.
• The NGR-TNF approach is currently under evaluation in a randomized Phase III trial for malignant pleural mesothelioma, indicating significant clinical interest.

Conclusions:

• Targeting tumor vasculature with specific peptides like NGR offers a viable strategy to enhance drug delivery to cancer cells.
• NGR-TNF represents a promising therapeutic agent for improving drug penetration in neoplastic tissues.
• These peptide-based strategies hold potential for improving the effectiveness of chemotherapy in various cancers, including malignant pleural mesothelioma.